Novak, Urban; Grob, T. J.; Baskaynak, G.; Peters, U. R.; Aebi, Stefan; Zwahlen, D.; Tschan, Mario; Kreuzer, K.-A.; Oppliger Leibundgut, Elisabeth; Cajot, J.-F.; Tobler, Andreas; Fey, Martin (2001). Overexpression of the p73 gene is a novel finding in high-risk B-cell chronic lymphocytic leukemia. Annals of oncology, 12(7), pp. 981-986. Oxford University Press 10.1023/A:1011153206003
|
Text
Annals Oncology_Novak 01.pdf - Published Version Available under License Publisher holds Copyright. Download (1MB) | Preview |
The p73 protein shares structural and functional similarities with the tumour-suppressor p53, but its role in neoplastic transformation is unknown. Alternative splicing leads to the expression of at least nine p73 C-terminal mRNA splice variants (alpha, beta, gamma, delta, epsilon, zeta, eta, eta1, theta). In this survey, we analyse the expression of p73 by real-time quantitative RT-PCR, its known C-terminal variants with an RT-PCR-Southern technique and by Western blot in samples of 51 patients with B-CLL, normal B lymphocytes from eight individuals, and five haematopoetic cell lines. p73alpha protein expression positively correlated with higher risk B-CLL stages (P = 0.046). Total p73 mRNA expression was higher (P = 0.01) and p73alpha protein more frequently detected (P = 0.008) in B-CLL compared with normal CD19+-B-lymphocytes. p73 C-terminal mRNA variants were expressed both in B-CLL and in normal B-lymphocytes, but their expression was biased since the gamma (P = 0.041), the theta (P < 0.001), and the eta variant (P = 0.033) prevailed in normal B-lymphocytes. In summary, we conclude that the accumulation of p73, the expression pattern of particular p73 variants and its link to progression may play a distinct role in the molecular pathology B-CLL.
Actions (login required)
 |
Edit item |